Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 117, Issue 26, Pages 15172-15181
Publisher
Proceedings of the National Academy of Sciences
Online
2020-06-13
DOI
10.1073/pnas.1918744117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
- (2019) Mike Sathekge et al. JOURNAL OF NUCLEAR MEDICINE
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- (2018) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
- (2018) Michael R. McDevitt et al. Nature Communications
- Early experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with mCRPC
- (2018) Andrei Gafita et al. JOURNAL OF NUCLEAR MEDICINE
- Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
- (2018) Marie Christine Hupe et al. Frontiers in Oncology
- Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095
- (2017) Ali Afshar-Oromieh et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A Prostate Cancer “ Nimbosus ”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies
- (2017) Melvin L.K. Chua et al. EUROPEAN UROLOGY
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- (2017) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Proof of Therapeutic Efficacy of a 177 Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model
- (2017) Jörg Schulz et al. JOURNAL OF NUCLEAR MEDICINE
- Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer
- (2016) Rohit Mehra et al. EUROPEAN UROLOGY
- 68 Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience
- (2016) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis
- (2016) D. L. J. Thorek et al. Science Translational Medicine
- ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1
- (2016) Simon-Peter Williams et al. Oncotarget
- Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2
- (2016) O. Vilhelmsson Timmermand et al. EJNMMI Research
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for -Particle Radioimmunotherapy of Cancer
- (2014) W. F. Maguire et al. JOURNAL OF NUCLEAR MEDICINE
- RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
- (2014) John R Prensner et al. LANCET ONCOLOGY
- Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens
- (2014) Riina-Minna Väänänen et al. UROLOGY
- Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6
- (2014) Oskar Vilhelmsson Timmermand et al. EJNMMI Research
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens
- (2013) Riina-Minna Väänänen et al. CLINICAL BIOCHEMISTRY
- ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients
- (2013) E. Baena et al. GENES & DEVELOPMENT
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Engineered antibodies for molecular imaging of cancer
- (2013) Anna M. Wu METHODS
- Androgen Signaling Promotes Translation of TMEFF2 in Prostate Cancer Cells via Phosphorylation of the α Subunit of the Translation Initiation Factor 2
- (2013) Ryan F. Overcash et al. PLoS One
- TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells
- (2013) Thomas Green et al. PROSTATE
- Radiation as an Immune Modulator
- (2013) Byron Burnette et al. SEMINARS IN RADIATION ONCOLOGY
- Differential Effects of Predosing on Tumor and Tissue Uptake of an 111In-Labeled Anti-TENB2 Antibody-Drug Conjugate
- (2012) C. A. Boswell et al. JOURNAL OF NUCLEAR MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Tumor Suppressor Activity of the Transmembrane Protein with Epidermal Growth Factor and Two Follistatin Motifs 2 (TMEFF2) Correlates with Its Ability to Modulate Sarcosine Levels
- (2011) Xiaofei Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
- (2011) M. J. Evans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
- (2011) Nigel M. Stapleton et al. Nature Communications
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started